uploads/2018/02/Imbruvica.png

Johnson & Johnson’s Oncology Segment’s Performance in 2017

By

Updated

Oncology segment’s revenue trends

In 4Q17, Johnson & Johnson’s (JNJ) Oncology segment generated revenues of $2.0 billion, which reflected ~40.0% growth on a year-over-year (or YoY) basis. In 4Q17, in the US market and international markets, the Oncology segment generated revenues of $891.0 million and ~$1.2 billion, respectively, compared to $595.0 million and $867.0 million in 4Q16.

In fiscal 2017, JNJ’s Oncology business reported revenues of $7.3 billion, which reflected ~25.0% YoY growth. In 2017, in the US market and international markets, JNJ’s Oncology segment generated revenues of $3.1 billion and $4.2 billion, respectively, compared to $2.3 billion and $3.5 billion in 2016, which reflected 33.0% and ~20.0% YoY growth.

Article continues below advertisement

Imbruvica’s revenue trends

In 4Q17, Johnson & Johnson’s (JNJ) Imbruvica generated revenues of $522.0 million, which reflected ~51.0% growth on a year-over-year (or YoY) basis. In 4Q17, in the US market and international markets, Imbruvica generated revenues of $219.0 million and $303.0 million, respectively, compared to $158.0 million and $188.0 million in 4Q16.

In fiscal 2017, JNJ’s Imbruvica reported revenues of $1.9 billion, which reflected ~51.3% growth on a YoY basis. In 2017, in the US market and international markets, Imbruvica reported revenues of $841.0 million and $1.1 billion, compared to $613.0 million and $638.0 million in 2016, which reflected ~37.0% and ~65.0% YoY growth.

Higher sales and growing market share primarily contributed to the revenue growth of Imbruvica. In the chronic lymphocytic leukemia drugs market, Imbruvica’s peers include Novartis’ (NVS) Arzerra, AbbVie’s (ABBV) Venclexta, Roche’s (RHHBY) Rituxan, and Gilead Sciences’ Zydelig.

Velcade’s revenue trends

In 4Q17, JNJ’s Velcade reported revenues of $271.0 million compared to $274.0 million in 4Q16, which reflected an ~1.0% YoY decline. In fiscal 2017, Velcade reported revenues of $1.1 billion and $1.2 billion, respectively.

Takeda Pharmaceuticals (TKPYY) commercializes Velcade in the US market while Johnson & Johnson commercializes the drug in Europe and the rest of the world. Takeda Pharmaceuticals and Johnson & Johnson jointly commercialize Velcade in Japan.

Advertisement

More From Market Realist